Cytomorphology of mature CD5-positive B-cell neoplasms

Czech version

Authors: D. Starostka; P. Mikula; D. Koláček; K. Chasáková; H. Taliánová; P. Miczková; L. Novosadová
Authors‘ workplace: Oddělení klinické hematologie, Nemocnice s poliklinikou, Havířov
Published in: Transfuze Hematol. dnes,23, 2017, No. 3, p. 117-126.
Category: Comprehensive Reports, Original Papers, Case Reports

Overview

Diagnosis of mature CD5-positive B-cell neoplasms is multidisciplinary. The goal of this study was to evaluate the diagnostic significance of cytomorphology in 233 diagnostic specimens of mature CD5-positive B-cell neoplasms. Cytomorphology assessment used light microscopy (Nikon Eclipse Ni). In the sample analysed, we diagnosed: CLL – both typical and atypical CLL (CLL/PL, pleomorphic CLL); SLL – small cell type; classical MCL, small cell, pleomorphic, blastoid and MZL-like variant, CD5+ MZL – small cell type, medium/large lymphocyte type, pleomorphic type and one with villous lymphocytes; CD5+ DLBCL – centroblastic, immunoblastic, anaplastic variant; unclassified cases – small cell type, medium/large lymphocyte type, pleomorphic type. In mature CD5-positive B-cell neoplasms, cytomorphology is a basic, rapid and low-cost method with high diagnostic value.

KEY WORDS:
cytomorphology – CD5 – B-cell – lymphoma – leukaemia

Sources

1. Swerdlow SH, Campo E, Lee Harris N, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Fourth Edition. IARC: Lyon 2008.

2. Oscier D, Else M, Matutes E, Morilla R, Strefford JC, Catovsky D. The morphology of CLL revisited: the clinical significance of prolymphocytes and correlations with prognostic/molecular markers in the LRF CLL4 trial. Br J Haematol 2016;174(5):767–775.

3. Matutes E, Wotherspoon A, Catovsky D. Differential diagnosis in chronic lymphocytic leukaemia. Best Pract Res Clin Haematol 2007;20(3):367–384.

4. Matutes E, Oscier D, Garcia-Marco J, et al. Trisomy 12 defines a group of CLL with atypical morphology: correlation between cytogenetic, clinical and laboratory features in 544 patients. Br J Haematol 1996;92(2):382–388.

5. Yatabe Y, Suzuki R, Matsuno Y, et al. Morphological spectrum of cyclin D1-positive mantle cell lymphoma: Study of 168 cases. Pathol Internat 2001;51:747–761.

6. Tiemann M, Schrader C, Klapper W, et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol 2005;131:29–38.

7. Peng S, Zhu F, You S, Gong M, Wen Z. Pathologic characteristics of bone marrow for CD5 positive small B cell lymphoma. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2016;41(4):374–379.

8. Wong K-F, Chan JKC, So JCC, Yu P-H. Mantle cell lymphoma in leukemic phase. Cancer 1999;86:850–857.

9. Matutes E, Parry-Jones N, Brito-Babapulle V, et al. The leukemic presentation of mantle-cell lymphoma: disease features and prognostic factors in 58 patients. Leuk Lymphoma 2004;45(10):2007–2015.

10. Matutes E, Oscier D, Montalban C, et al. Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia 2008;22:487–495.

11. Baseggio L, Traverse-Glehen A, Petinataud F, Callet-Bauchu E, Berger F, Ffrench M. CD5 expression identifies a subset of splenic marginal zone lymphomas with higher lymphocytosis: a clinico-pathological, cytogenetic and molecular study of 24 cases. Haematologica 2010;95:604–612.

12. Trousard X, Valensi F, Duchayne E, et al. Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients GFHC. Br J Haematol 1996;93(3):731–736.

13. Papadaki T, Stamatopoulos K, Belessi C, et al. Splenic marginal zone lymphoma: on or more entities? A histologic, immunohistochemical and molecular study of 42 cases. Am J Surg Pathol 2007;31(3):438– 446.

14. Murphy BA, Meda BA, Buss DH, Geisinger KR. Marginal zone and mantle cell lymphomas: assessment of cytomorphology in subtyping small B-cell lymphomas. Diagn Cytopathol 2003;28(3):126–130.

15. Harmon CM, Smith LB. B-cell non-Hodgkin lymphomas with plasmacytic differentiation. Surg Pathol Clin 2016;9(1):11–28.

16. Swerdlow SH, Kuzu I, Dogan A, et al. The many faces of small B cell lymphomas with plasmacytic differentiation and the contribution of MYD88 testing. Virchows Arch 2016;468(3):259–275.

17. Schlette E, Bueso-Ramos C, Giles F, Glassman A, Hayes K, Medeiros LJ. Mature B-cell leukemias with more than 55% prolymphocytes. A heterogeneous group that includes an unusual variant of mantle cell lymphoma. Am J Clin Pathol 2001;115(4):571–581.

18. Oscier DG, Matutes E, Copplestone A, et al. Atypical lymphocyte morphology: an adverse prognostic factor for disease progression in stage A CLL independent of trisomy 12. Br J Haematol 1997;98(4):934–939.

19. Hjalmar V, Kimby E, Matutes E, Sundström C, Wallvik J, Hast R. Atypical lymphocytes in B-cell chronic lymphocytic leukemia and trisomy 12 studied by conventional staining combined with fluorescence in situ hybridization. Leuk Lymphoma 2000;37(5-6): 571–576.

20. Wong KF, So CC, Chan JK. Nucleolated variant of mantle cell lymphoma with leukemic manifestations mimicking prolymphocytic leukemia. Am J Clin Pathol 2002;117(2):246–251.

21. Ott G, Kalla J, Hanke A, et al. The cytomorphological spectrum of mantle cell lymphoma is reflected by distinct biological features. Leuk Lymphoma 1998;32(1-2):55–63.

22. Matutes E, Morilla R, Owusu-Ankomah K, Houlihan A, Catovsky D. The immunophenotype of splenic lymphoma with villous lymphocytes and its relevance to the differential diagnosis with other B-cell disorders. Blood 1994;83(6):1558–1562.

23. Seok Y, Kim J, Choi JR, et al. CD5-negative blastoid variant mantle cell lymphoma with complex CCND1/IGH and MYC aberrations. Ann Lab Med 2012;32:95–98.

24. Morice WG, Hodnefield JM, Kurtin PJ, et al. An unusual case of leukemic mantle cell lymphoma with a blastoid component showing loss of CD5 and aberrant expression of CD10. Am J Clin Pathol

2004;122:122–127.

25. Carbone A, Gloghini A, Kwong ZL, Younes A. Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy. Ann Hematol 2014;93(8):1263–1277.

26. Menon MP, Pittaluga S, Jaffe ES. The Histological and Biological Spectrum of Diffuse Large B-cell Lymphoma in the WHO Classification. Cancer J 2012;18(5):411–420.

27. Ott G, Ziepert M, Klapper W, et al. Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. Blood 2010;116(23):4916–4925.

Labels

Haematology Internal medicine Clinical oncology

Blastic plasmacytoid dendritic cell neoplasm: case report and literature review

Long-term treatment results of chronic myelomonocytic leukaemia in selected haematological centres

Acquired angioedema with C1 inhibitor deficiency in a patient with low-grade B-lymphoma and the effect of underlying disease treatment on angioedema manifestations

Idarucizumab: a single centre experience

Article was published in

Transfusion and Haematology Today

2017 Issue 3